Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trialAthol U. Wells, Daniel F. Dilling, Wim Wuyts et al.|The Lancet Respiratory Medicine|2020Cited by 558
Acute exacerbations of progressive-fibrosing interstitial lung diseasesMartin Kolb, Shane Shapera, Benjamin Bondue et al.|European Respiratory Review|2018Cited by 180
Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic DiseaseWim Wuyts, Elisabeth Bendstrup, Marlies Wijsenbeek et al.|Respiration|2019Cited by 93
In situ cancer diagnosis through online plasmonicsMédéric Loyez, Christophe Caucheteur, Jean-Charles Larrieu et al.|Biosensors and Bioelectronics|2019Cited by 86